Publications

  1. Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU, Translational Breast Cancer Research Consortium. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 May 1; 37 (13):1081-1089 Epub 2019 Mar 12
    View PubMed
  2. Duma N, Gast KC, Choong GM, Leon-Ferre RA, O'Sullivan CC. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer? Curr Oncol Rep. 2018 Jun 8; 20 (8):63 Epub 2018 June 08
    View PubMed
  3. O'Sullivan CC, Loprinzi CL, Haddad TC. Updates in the Evaluation and Management of Breast Cancer. Mayo Clin Proc. 2018 Jun; 93 (6):794-807
    View PubMed
  4. O'Sullivan CC, Van Houten HK, Sangaralingham LR, Leal AD, Shinde S, Liu H, Ettinger D, Loprinzi CL, Ruddy KJ. Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy. J Natl Compr Canc Netw. 2018 Mar; 16 (3):294-299
    View PubMed
  5. Nowsheen S, Viscuse PV, O'Sullivan CC, Sandhu NP, Haddad TC, Blaes A, Klemp J, Nhola L, Herrmann J, Ruddy KJ. Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer. Curr Breast Cancer Rep. 2017 Sep; 9 (3):173-182 Epub 2017 July 14
    View PubMed
  6. Burotto M, Edgerly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz JG, O'Sullivan C, Madan R, Fojo T. A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma. Oncologist. 2017 Aug; 22 (8):888-e84 Epub 2017 July 05
    View PubMed
  7. O'Sullivan CC, Davarpanah NN, Abraham J, Bates SE. Current challenges in the management of breast cancer brain metastases. Semin Oncol. 2017 Apr; 44 (2):85-100 Epub 2017 July 08
    View PubMed
  8. O'Sullivan CC, Ruddy KJ. Management of Potential Long-Term Toxicities in Breast Cancer Patients. Curr Breast Cancer Rep. 2016 Dec; 8: (4)183-192.
    View PubMed
  9. O'Sullivan CC, Lindenberg M, Bryla C, Patronas N, Peer CJ, Amiri-Kordestani L, Davarpanah N, Gonzalez EM, Burotto M, Choyke P, Steinberg SM, Liewehr DJ, Figg WD, Fojo T, Balasubramaniam S, Bates SE. ANG1005 for breast cancer brain metastases: correlation between (18)F-FLT-PET after first cycle and MRI in response assessment. Breast Cancer Res Treat. 2016 Nov; 160 (1):51-59 Epub 2016 Sept 12
    View PubMed
  10. O'Sullivan CC. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update. Expert Opin Pharmacother. 2016 Aug; 17 (12):1657-67 Epub 2016 June 27
    View PubMed
  11. O'Sullivan CC, Bates SE. Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer. Oncologist 2016 May; 21 (5):523-6 Epub 2016 Apr 22
    View PubMed
  12. O'Sullivan CC, Holmes E, Campbell C, Bradbury I, Zujewski JA, Gelber RD. Reply to A. Oguz et al. J Clin Oncol. 2016 Feb 20; 34: (6)640-1.
    View PubMed
  13. Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, Kinders RJ, Cao L, Peer CJ, Figg WD, Annunziata CM. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer. 2016 Feb 15; 122: (4)588-97.
    View PubMed
  14. Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016 Jan; 155: (2)235-51.
    View PubMed
  15. O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors View PubMed
  16. O'Sullivan CC. Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors. Int J Cancer Clin Res. 2015; 2: (4).
    View PubMed
  17. O'Sullivan CC, Smith KL. Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer. Curr Breast Cancer Rep. 2014 Sep 1; 6: (3)169-182.
    View PubMed
  18. O'Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang SX, Nguyen D, Balasubramaniam S, Fojo T. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab. 2014 Apr; 99: (4)1291-7.
    View PubMed
  19. O'Sullivan CC, Connolly RM. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer. Oncology (Williston Park). 2014 Mar; 28: (3)186-94, 196.
    View PubMed
  20. O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol. 2014; 4:42.
    View PubMed
  21. O'Sullivan CC, Ozdemirli M, Bazylewicz M, Cheson BD. Complete response to brentuximab vedotin in a transplant-naive patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma. Clin Adv Hematol Oncol. 2013 Jun; 11: (6)382-5.
    View PubMed
  22. O'Sullivan CC, Swain SM. Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. Expert Opin Biol Ther. 2013 May; 13: (5)779-90.
    View PubMed
  23. O'Sullivan C, Kennedy , MJ. Targeted therapies in breast cancer Irish Medical News.;().
  24. O'Sullivan C, Carney , DN. Clinical case study in osteosarcoma Hospital Doctor. 2010.